Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|Advanced Breast Cancer|HER2-positive Breast Cancer
Interventions: DRUG: Margetuximab|DRUG: Tucatinib|DRUG: Capecitabine
Sponsor: MedSIR
Collaborators: MacroGenics|Seagen Inc.